Helmholtz Gemeinschaft


Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas

PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
[img] Other (Supplementary Material)

Item Type:Article
Title:Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas
Creators Name:Arnold, A. and Daum, S. and von Winterfeld, M. and Berg, E. and Hummel, M. and Rau, B. and Stein, U. and Treese, C.
Abstract:INTRODUCTION: The tight junction molecule Claudin 18.2 is selectively expressed in healthy and malignant gastric epithelial tissue and is a promising therapy target for high Claudin 18.2 expressing adenocarcinomas of the esophagogastric junction and stomach (AEG/S). METHODS: This study analyzed the prevalence, characteristics and prognostic impact of Claudin 18.2 expression in primary tumor, lymph node and distant metastasis in a large Caucasian AGE/S cohort with 414 patients. RESULTS: Claudin 18.2 was highly expressed in 17.1% of primary tumors, 26.7% of lymph node metastasis and 16.7% of distant metastasis. High Claudin 18.2 expression in lymph node metastasis and primary tumors correlated significantly (p < 0.001). High expression of Claudin 18.2 was neither associated with histomorphogical subtype, or tumor state, nor with overall survival. CONCLUSION: In Caucasian AEG/S patients, 17.1% appeared to be eligible for an anti-Claudin 18.2 therapy. Claudin 18.2 expression itself has no impact on prognosis and is not related to any tumor subtype.
Keywords:Claudin 18.2, Claudiximab, IMAB362, Gastric Cancer, Esophageal Cancer
Source:Clinical and Translational Oncology
Page Range:2357-2363
Date:December 2020
Official Publication:https://doi.org/10.1007/s12094-020-02380-0
PubMed:View item in PubMed

Repository Staff Only: item control page


Downloads per month over past year

Open Access
MDC Library